<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931255</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00042201</org_study_id>
    <nct_id>NCT00931255</nct_id>
  </id_info>
  <brief_title>Tacrolimus to Sirolimus Conversion for Delayed Graft Function</brief_title>
  <acronym>RAPA</acronym>
  <official_title>Delayed Tacrolimus to Sirolimus Conversion in Renal Transplant Recipients With Delayed Graft Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of conversion from
      tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft
      function (DGF)and slow graft function (SGF) in improving graft function and delaying chronic
      allograft nephropathy. The investigators hypothesize that conversion from tacrolimus to
      sirolimus in renal transplant recipients with DGF/SGF in early months after surgery will
      improve graft function and decrease the progression of graft fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible study subjects will be randomized into two groups 8-18 weeks after surgery. One
      group will be maintained on tacrolimus according to the standard of care at our center. In
      the second group tacrolimus will be converted to sirolimus, with one week overlap between
      sirolimus therapy and tacrolimus taper. All the deceased donor kidney transplant recipients
      transplanted at our center who experience DGF/SGF are eligible for inclusion in this study,
      if they meet the inclusion/exclusion criteria as detailed later.

      Data will be collected on patient demographics, duration on dialysis, history of diabetes and
      chronic hepatitis C, previous transplantation, PRA, donor source, warm and cold ischemia
      time, donor demographics and comorbidity such as diabetes and hypertension, serum creatinine
      at the time of organ removal, early graft function, number of dialysis treatments after
      transplantation, induction agent and immunosuppressive regimen including the dose or level of
      the drugs at 3, 6, 9, 12, 18, and 24 months. Similar data regarding use of ACE
      inhibitors/ARBs, erythropoietic agents, number of anti-hypertensives and lipid lowering
      agents will be collected. In addition, the following tests and procedures will be obtained
      for this study.

        1. GFR measurement by cold iothalamate method at one year after transplantation.

        2. Evaluation of routine surveillance graft biopsies for chronic changes at 3 and 12 months
           posttransplant by morphometric analysis.

        3. Spot urine protein, albumin, and creatinine measurement at 3 and 12 months.

        4. Estimate GFR at 3, and 12 months using MDRD, CG, and Nankivell formulas

        5. Examine the surveillance and indicated biopsies for acute rejection and BK nephropathy.

        6. Fasting lipid profile at 3 and 12 months for all patients, and 24 months for those with
           at least 2 years of follow up.

        7. Office blood pressure measurements at 3 and 12 months for all patients, and 24 months
           for those with at least 2 years of follow up.

        8. Measurement of CRP, IL-6, and MCP at 3 and 12 months.

      The safety measures will include:

      Incidence of leukopenia (WBC &lt; 3000) or thrombocytopenia (PLT &lt; 100,000); hemoglobin level at
      12 months; proteinuria at 12 months; incidence of oral aphthous ulcers; incidence of new
      onset diabetes, incidence of CMV infection and rate of drug withdrawal due to side effects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was stopped because of slow recruitment.
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Composite Endpoint of Reduction of e eGFR at One Year by More Than 15% &amp; the Progression in Fibrosis Score at One Year by &gt;=20% Compared With the Baseline Values</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR From Baseline to 1-year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival (Actual, Actuarial)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Rejection (Actual, Actuarial)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BK Nephropathy (Cumulative)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Marker : CRP From Baseline</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Marker, IL-6 From Baseline</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Marker, MCP, From Baseline</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Kidney Transplant</condition>
  <condition>Delayed Graft Function</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg, PO , daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>FK506, Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamune, Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age =&gt; 18.

          2. Recipient of a deceased donor kidney transplant.

          3. Delayed graft function, defined as need for dialysis during first week after surgery
             or slow graft function, defined as creatinine &gt;=3.0 by post-op day 5 without requiring
             dialysis

          4. Stable serum creatinine for 2 weeks prior to enrollment.

          5. Able to give informed consent.

          6. Compliant with medical regimen and clinic visits.

        Exclusion Criteria:

          1. Episode of acute rejection within 4 weeks prior to enrollment.

          2. Calculated GFR &lt; 30 ml/min.

          3. Interstitial fibrosis &amp; tubular atrophy in transplant biopsy higher than grade II
             (Banff&quot;05 update).

          4. Proteinuria &gt; 500 mg/24 h or spot urine protein/creatinine &gt; 0.5.

          5. Total fasting cholesterol level &gt; 300 mg/dl or triglyceride &gt; 500 mg/dl despite
             optimal lipid lowering therapy.

          6. Recipient of pancreas or liver allografts.

          7. Leukopenia (WBC &lt; 3000 mm3) within 2 weeks prior to enrollment.

          8. Leukopenia (WBC &lt; 2000 mm3) within 4 weeks prior to enrollment.

          9. Thrombocytopenia (platelets count &lt; 100,000/mm3) within 2 weeks prior to enrollment.

         10. Unwilling to comply with study protocol.

         11. Enrollment in another drug trial that precludes use of sirolimus.

         12. Diagnosis of malignancy within 2 years prior to enrollment, except adequately treated
             non-melanoma skin cancer.

         13. For women, pregnancy.

         14. Allergy to iodine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdolreza Haririan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <results_first_submitted>December 31, 2014</results_first_submitted>
  <results_first_submitted_qc>March 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2018</results_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Abdoleza Haririan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>sirolimus</keyword>
  <keyword>delayed graft function</keyword>
  <keyword>Graft survival</keyword>
  <keyword>Acute rejection</keyword>
  <keyword>Chronic allograft nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tacrolimus</title>
          <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
        </group>
        <group group_id="P2">
          <title>Sirolimus</title>
          <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Follow up biopsy not done</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus</title>
          <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
        </group>
        <group group_id="B2">
          <title>Sirolimus</title>
          <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="9.7"/>
                    <measurement group_id="B2" value="49.9" spread="10.1"/>
                    <measurement group_id="B3" value="51.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Composite Endpoint of Reduction of e eGFR at One Year by More Than 15% &amp; the Progression in Fibrosis Score at One Year by &gt;=20% Compared With the Baseline Values</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite Endpoint of Reduction of e eGFR at One Year by More Than 15% &amp; the Progression in Fibrosis Score at One Year by &gt;=20% Compared With the Baseline Values</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR</title>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="15.2"/>
                    <measurement group_id="O2" value="53.7" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in eGFR From Baseline to 1-year</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in eGFR From Baseline to 1-year</title>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" spread="11.5"/>
                    <measurement group_id="O2" value="1.57" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Survival (Actual, Actuarial)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival (Actual, Actuarial)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute Rejection (Actual, Actuarial)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Rejection (Actual, Actuarial)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of BK Nephropathy (Cumulative)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of BK Nephropathy (Cumulative)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Marker : CRP From Baseline</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Marker : CRP From Baseline</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1668" spread="9403"/>
                    <measurement group_id="O2" value="4510" spread="14495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Marker, IL-6 From Baseline</title>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Marker, IL-6 From Baseline</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="8.53"/>
                    <measurement group_id="O2" value="6.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Marker, MCP, From Baseline</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Marker, MCP, From Baseline</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-787.5" spread="693.9"/>
                    <measurement group_id="O2" value="-965.2" spread="753.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus</title>
          <description>Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
Tacrolimus: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol</description>
        </group>
        <group group_id="E2">
          <title>Sirolimus</title>
          <description>5 mg, PO , daily
Sirolimus: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CMV viremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was stopped because of slow enrollment. Hence, the target enrollment number was not achieved.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Abdolreza Haririan, MD</name_or_title>
      <organization>UMaryland</organization>
      <phone>410-328-5720</phone>
      <email>ahariria@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

